BioCentury
ARTICLE | Clinical News

Taxotere docetaxel: Phase III data; marketed to treat locally advanced or metastatic breast cancer after failure of prior chemotherapy

May 24, 1999 7:00 AM UTC

In a 373-patient U.S. Phase III trial, the one-year survival rate of patients treated with docetaxel was 32 percent compared to 19 percent of patients treated with either vinorelbine or ifosfamide. Da...